0I1B Stock Chart & Stats
$29.16
$0.93(3.19%)
At close: 4:00 PM EDT
$29.16
$0.93(3.19%)
Day’s Range― - ―
52-Week Range$18.47 - $33.45
Previous CloseN/A
Volume31.00
Average Volume (3M)418.00
Market Cap
$1.10B
Enterprise Value$2.65K
Total Cash (Recent Filing)$12.56M
Total Debt (Recent Filing)$1.37B
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Nov 11, 2026EPS Estimate
0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-19.40
Shares Outstanding57,669,495
10 Day Avg. Volume754
30 Day Avg. Volume418
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.02
Price to Sales (P/S)0.67
P/FCF Ratio75.96
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$39.10Price Target Upside34.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)3.64
Revenue Forecast (FY)$2.34B
Bulls Say, Bears Say
Bulls Say
Diversified Musculoskeletal Care PortfolioA portfolio spanning reconstruction, trauma, prevention and rehabilitation gives Enovis multiple demand channels within musculoskeletal care. This breadth can support cross-selling, reduce reliance on one procedure category, and deepen relationships with hospitals, surgeons and other care providers over the medium term.
Positive And Improving Cash GenerationPositive and improving operating cash flow indicates that the business is generating internal liquidity despite reported losses. TTM free cash flow also provides funding for investment and debt service, although sustained conversion still needs to be demonstrated through a full operating cycle.
Expansion Into Surgical RoboticsAdding robotic automation and enabling technologies broadens Enovis beyond conventional implants and instruments, potentially strengthening its surgical platform and strategic relevance to hospitals. The Grenoble center of excellence may also build specialized capabilities that support future product development and adoption.
Bears Say
Severe And Persistent Reported LossesVery large net losses and deeply negative margins show that Enovis has not yet demonstrated durable earnings power. Continued losses can limit reinvestment flexibility, weaken returns on the existing asset base, and make future operating performance highly dependent on a successful profitability recovery.
Higher Leverage And Financing ExposureThe sharp increase in leverage leaves debt near the level of equity and reduces financial flexibility while profitability remains weak. Higher obligations can constrain capital allocation, increase sensitivity to operating setbacks, and make it harder to fund strategic initiatives without relying on additional borrowing.
Robotics Deal Creates Near-term Margin And Funding PressureAlthough the robotics acquisition expands the platform, its funding will draw on cash and the revolving credit facility while management expects a near-term EBITDA margin headwind. These effects could pressure cash conversion and leverage before anticipated margin improvement from 2028 onward.
Enovis News
0I1B FAQ
What was Enovis’s price range in the past 12 months?
Enovis lowest share price was $18.46 and its highest was $33.45 in the past 12 months.
What is Enovis’s market cap?
Enovis’s market cap is $1.10B.
When is Enovis’s upcoming earnings report date?
Enovis’s upcoming earnings report date is Nov 11, 2026 which is in 61 days.
How were Enovis’s earnings last quarter?
Enovis released its earnings results on Aug 06, 2026. The company reported $0.9 earnings per share for the quarter, beating the consensus estimate of $0.847 by $0.053.
Is Enovis overvalued?
According to Wall Street analysts Enovis’s price is currently Undervalued.
Does Enovis pay dividends?
Enovis does not currently pay dividends.
What is Enovis’s EPS estimate?
Enovis’s EPS estimate is 0.77.
How many shares outstanding does Enovis have?
Enovis has 57,669,495 shares outstanding.
What happened to Enovis’s price movement after its last earnings report?
Enovis reported an EPS of $0.9 in its last earnings report, beating expectations of $0.847. Following the earnings report the stock price went down -12.475%.
Which hedge fund is a major shareholder of Enovis?
Currently, no hedge funds are holding shares in GB:0I1B
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enovis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.10 (34.09% Upside)
$39.10 (34.09% Upside)
Blogger Sentiment
Bullish
GB:0I1B Sentiment 100%
Sector Average 61%
Sector Average 61%
Insider Transactions
Bought Shares
Worth $519.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.56%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-25.00%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Enovis
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.
0I1B Company Deck
0I1B Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call showed solid operational execution and clear commercial momentum—particularly in Recon and extremities—with meaningful innovation catalysts (Arvis, Nebula), margin expansion at the gross level, EPS growth, and improved free cash flow. However, offsetting risks include tariff costs (~$4M), international volatility including Middle East exposure (~$1–2M/month), a Q1 selling-days headwind (~240 bps), a conservative stance on guidance, and an SEC-driven change to adjusted EBITDA presentation that reduces non-GAAP comparability. On balance, positive fundamental performance and a constructive outlook outweigh the near-term headwinds and reporting adjustments.View all GB:0I1B earnings summaries0I1B Stock 12 Month Forecast
Average Price Target
$39.10
▲(34.09% Upside)